Market access update
Market access update
Written by Jeff Weisel
There is a growing focus and spending in Asia-Pacific (APAC) markets, particularly China.
This is, in part, driven by pro-innovation and pro‑biotechnology policy trends in the region, which make the country an increasingly important and attractive market for biopharmaceutical manufacturers globally.
To put the size of the opportunity in APAC into context, Asia comprises about 60% of the global population but only accounts for about 30% of all global pharmaceutical spending.1 This figure, however, is steadily increasing as several APAC countries, including China, are actively developing their own R&D-based biopharma sector, the region’s healthcare burden rises, and more companies are finding ways to navigate APAC markets.
While some APAC markets, such as Japan and Australia, have been on the industry radar for decades and have mature healthcare and payer systems, China has emerged and evolved significantly, especially in the past decade.
International manufacturers have been adapting to the value and opportunity there, moving beyond an earlier focus on marketing established products to now regarding China as a potential market for their latest innovative medicines and a strategic global opportunity alongside their home markets in the USA and Europe.
There continues to be significant investment in the development of China’s healthcare industry, with a commitment from the Chinese government to continue laying the groundwork for an innovative and thriving biopharma sector. This includes:
Consequently, some of the historical challenges associated with the Chinese healthcare, regulatory, and payer systems have become less complicated to navigate, including:
Global biopharmaceutical manufacturers have been finding success in this market, but this success has not come overnight; these companies have made inroads built on significant time and investment. The increasing attention on China from the global industry has illuminated several implications for evidence-generation and launch strategy:
These APAC insights feature in the Fishawack Health paper: “Archetyping: rethinking go-to-market expectations to drive commercial success.”
In the paper, experts provide an in-depth introduction to archetypes and share a new two-step archetyping framework. This framework ensures the market and product opportunity is robustly analyzed and clear actions are defined to deliver commercialization success, from asset and trial strategy through go‑to‑market model development, investment decisions, and launch.
Building a healthier Asia